Bai C, Xin X, Yang Y, Qu F, Fan Z
Front Oncol. 2025; 14:1497272.
PMID: 40051607
PMC: 11883444.
DOI: 10.3389/fonc.2024.1497272.
Howell S, Howell A
Adv Exp Med Biol. 2025; 1464():449-474.
PMID: 39821038
DOI: 10.1007/978-3-031-70875-6_22.
Hanf D, Fasching P, Gass P, Beckmann M, Hack C, Heindl F
Breast Cancer Res Treat. 2024; 210(1):125-134.
PMID: 39586971
PMC: 11787164.
DOI: 10.1007/s10549-024-07545-x.
Matsubara K, Hayakawa N, Aida K, Koike J, Kikuchi E
Int Cancer Conf J. 2024; 13(3):296-300.
PMID: 38962031
PMC: 11217202.
DOI: 10.1007/s13691-024-00681-7.
Achounna A, Ordaz-Rosado D, Garcia-Quiroz J, Morales-Guadarrama G, Milo-Rocha E, Larrea F
Int J Mol Sci. 2024; 25(6).
PMID: 38542136
PMC: 10970597.
DOI: 10.3390/ijms25063165.
Concurrent factors associated with adherence to adjuvant endocrine therapy among women with non-metastatic breast cancer.
Walsh E, Walsh L, Hernand M, Horick N, Antoni M, Temel J
J Cancer Surviv. 2024; .
PMID: 38401012
DOI: 10.1007/s11764-024-01556-9.
Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case-cohort analysis.
Albers F, Lou M, Dashti S, Swain C, Rinaldi S, Viallon V
Cancer Causes Control. 2024; 35(6):921-933.
PMID: 38363402
PMC: 11130059.
DOI: 10.1007/s10552-024-01856-6.
Antibodies toward Na,HCO-cotransporter NBCn1/SLC4A7 block net acid extrusion and cause pH-dependent growth inhibition and apoptosis in breast cancer.
Axelsen T, Olesen C, Khan D, Mohammadi A, Bouzinova E, Nielsen C
Br J Cancer. 2024; 130(7):1206-1220.
PMID: 38310186
PMC: 10991555.
DOI: 10.1038/s41416-024-02591-0.
Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy.
Dou H, Li F, Wang Y, Chen X, Yu P, Jia S
Diagn Pathol. 2024; 19(1):5.
PMID: 38178166
PMC: 10765627.
DOI: 10.1186/s13000-023-01433-6.
Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study.
Cheung Y, Hoermann R, Van K, Wu D, Healy J, Halim B
Endocr Connect. 2023; 12(10).
PMID: 37522858
PMC: 10503251.
DOI: 10.1530/EC-23-0076.
Visualized machine learning models combined with propensity score matching analysis in single PR-positive breast cancer prognosis: a multicenter population-based study.
Li C, Hui Y, Wei X, Yao P, Jia Y, Liu M
Am J Cancer Res. 2023; 13(6):2234-2253.
PMID: 37424799
PMC: 10326595.
Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.
Moller N, Boonen D, Feldner E, Hao Q, Larsen M, Laenkholm A
Sci Rep. 2023; 13(1):8536.
PMID: 37237042
PMC: 10220031.
DOI: 10.1038/s41598-023-35755-8.
Single progesterone receptor-positive phenotype has the similar clinicopathological features and outcome as triple-negative subtype in metastatic breast cancer.
Luo Y, Pu H, Li F, Qian S, Chen J, Zhao X
Front Oncol. 2023; 13:1029648.
PMID: 36910652
PMC: 9998980.
DOI: 10.3389/fonc.2023.1029648.
Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay.
Hurson A, Hamilton A, Olsson L, Kirk E, Sherman M, Calhoun B
Breast Cancer Res Treat. 2023; 199(1):147-154.
PMID: 36892725
PMC: 10147733.
DOI: 10.1007/s10549-023-06888-1.
Muscle strength is associated with fracture risk obtained by fracture risk assessment tool (FRAX) in women with breast cancer.
Bernabe R, de Souza Vieira M, de Souza V, Gomes Fontana L, Albergaria B, Marques-Rocha J
BMC Cancer. 2022; 22(1):1115.
PMID: 36320019
PMC: 9623985.
DOI: 10.1186/s12885-022-10203-4.
Integrating and validating automated digital imaging analysis of estrogen receptor immunohistochemistry in a fully digital workflow for clinical use.
Shafi S, Kellough D, Lujan G, Satturwar S, Parwani A, Li Z
J Pathol Inform. 2022; 13:100122.
PMID: 36268080
PMC: 9577060.
DOI: 10.1016/j.jpi.2022.100122.
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Lopez-Knowles E, Detre S, Hills M, Schuster E, Cheang M, Tovey H
Breast Cancer Res. 2022; 24(1):61.
PMID: 36096872
PMC: 9466340.
DOI: 10.1186/s13058-022-01556-6.
Correlation of tumour subtype with long-term outcome in small breast carcinomas: a Swedish population-based retrospective cohort study.
Rask G, Nazemroaya A, Jansson M, Wadsten C, Nilsson G, Blomqvist C
Breast Cancer Res Treat. 2022; 195(3):367-377.
PMID: 35933487
PMC: 9464733.
DOI: 10.1007/s10549-022-06691-4.
Vitamin D: an essential adjuvant therapeutic agent in breast cancer.
Thabet R, Gomaa A, Matalqah L, Shalaby E
J Int Med Res. 2022; 50(7):3000605221113800.
PMID: 35883275
PMC: 9340350.
DOI: 10.1177/03000605221113800.
Prognostic and Predictive Value of /Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis.
Jeffreys S, Becker T, Khan S, Soon P, Neubauer H, de Souza P
Front Endocrinol (Lausanne). 2022; 13:895729.
PMID: 35784572
PMC: 9249016.
DOI: 10.3389/fendo.2022.895729.